word is that Roche will not be extending their collaberation,...

word is that Roche will not be extending their collaberation, which leaves Pfizer and Medimmune as the two likely (short-term'ish) prospects. Unfortunately I don't think they have to decide until the middle of the year.

I think this is making everyone nervous because, as Andrew says, they really have nothing until a pharma partner decides they will move forward with the specific peptide. So, no extension of the collaberations undermines validity of the science. The flip side being that these guys are all pretty smart and they're not going to enter collaberations in the first place without something reasonably solid.

Proofs in the pudding I guess.

In the meantime a complete lack of news / updates / spruiking has led us to the lowest share price since Feb 2009, and even then it was a brief drop. Apart from that this is the lowest price for these shares ever.

Now, tell me their communication strategy is working...!!!